Treatment Advances

Our Treatment Advances articles cover treatment option updates, new combinations of treatments, FDA approval news, and more.

Headlines All Categories Treatment Advances Navigating Your Health Core Education Patient Stories HealthTree Research Conferences Clinical Trials HealthTree Programs HealthTree Press

Recent Articles

Mosunetuzumab + Polatuzumab Promising Trial Results for R/R LBCL

March 06, 2025

Explore recent trial results on mosunetuzumab + polatuzumab for R/R LBCL, showing higher response rates & longer remission vs. standard care.

How Effective is Tab-cel for EBV+ Post-Transplant Lymphoma?

March 03, 2025

Learn how an off-the-shelf T-cell therapy called tab-cel is supporting PTLD patients and how you may be eligible to join the study.

Brentuximab Vedotin (Adcetris) Combination Now FDA-Approved for R/R LBCL Patients Ineligible for Transplant or CAR-T

February 13, 2025

FDA approves a new combo therapy for relapsed/refractory large B-cell lymphoma, offering support for patients ineligible for transplant or CAR T-cell therapy.

Real-World Data Shows Improved Outcomes for Black Patients with DLBCL

February 03, 2025

New real-world data shows improved survival outcomes for Black DLBCL patients, highlighting the impact of R-CHOP and better insurance coverage.

Azer-cel, a New CAR T-Cell Therapy for DLBCL

November 08, 2024

Explore an innovative trial using Azer-cel, an allogeneic CAR T-cell therapy, for relapsed DLBCL patients, focusing on safety and effectiveness.

How One DLBCL Therapy Is Proving Its Worth: Three Years Later

October 15, 2024

After three years since its original Phase III trial, lisocabtagene maraleucel (liso-cel) is still proving effective for relapsed/refractory DLBCL patients.

Large B-Cell Lymphoma with CNS Involvement: Treatment Options and Future Directions

September 16, 2024

Learn about the challenges of treating DLBCL with central nervous system involvement, explore available treatment options, and discover the latest research.